Heart failure with preserved ejection fraction: Pathophysiology and emerging therapies

Cardiovascular Therapeutics

Volumn 29, Issue 4, 2011, Pages

  From, Aaron M ^a   Borlaug, Barry A ^a  

^a Mayo Clinic   (United States)

Author keywords

Diastole; Heart failure; Heart failure with preserved ejection fraction; Hypertension; Pathophysiology; Treatment

Indexed keywords

ALDOSTERONE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMLODIPINE; BETA ADRENERGIC RECEPTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CARVEDILOL; CHLORTALIDONE; DIGOXIN; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; NEBIVOLOL; NEUROHORMONE; NITRATE; PERINDOPRIL; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROPRANOLOL; RAMIPRIL; ROSUVASTATIN; SPIRONOLACTONE; UNINDEXED DRUG; VALSARTAN; VERAPAMIL; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANEMIA; ATHEROSCLEROSIS; AUTONOMIC DYSFUNCTION; CARDIOVASCULAR RESERVE FUNCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONOTROPISM; COMORBIDITY; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY DILATATION; DIASTOLIC DYSFUNCTION; DISEASE EXACERBATION; DYSPNEA; EXERCISE; EXERCISE TOLERANCE; HEART DISEASE; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE OVERLOAD; HEMODYNAMICS; HORMONAL REGULATION; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY ARTERY STENOSIS; KIDNEY REVASCULARIZATION; LEFT ATRIAL DYSFUNCTION; MORTALITY; MUSCLE DISEASE; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVASCULARIZATION; REVIEW; RISK BENEFIT ANALYSIS; SKELETAL MUSCLE DYSFUNCTION; TACHYCARDIA; TISSUE DOPPLER IMAGING; VASCULAR DYSFUNCTION; VASCULAR STIFFENING; VENTRICULAR SYSTOLIC STIFFENING; DIASTOLE; HEART MUSCLE REVASCULARIZATION; HEART STROKE VOLUME; SYSTOLE;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIASTOLE; DIURETICS; EXERCISE; HEART FAILURE; HUMANS; MYOCARDIAL REVASCULARIZATION; STROKE VOLUME; SYSTOLE;

EID: 79960259253     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00133.x     Document Type: Review

References (155)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-259.
2. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355:260-269.
3. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003;362:777-781.
4. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338-2345.
5. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456-2467.
6. Kitzman DW, Higginbotham MB, Cobb FR, Sheikh KH, Sullivan MJ. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: Failure of the Frank-Starling mechanism. J Am Coll Cardiol 1991;17:1065-1072.
7. Gandhi SK, Powers JC, Nomeir AM, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001;344:17-22.
8. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004;350:1953-1959.
9. Westermann D, Kasner M, Steendijk P, et al. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation 2008;117:2051-2060.
10. Lam CS, Roger VL, Rodeheffer RJ, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 2007;115:1982-1990.
11. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: Implications for systolic and diastolic reserve limitations. Circulation 2003;107:714-720.
12. Yip G, Wang M, Zhang Y, Fung JW, Ho PY, Sanderson JE. Left ventricular long axis function in diastolic heart failure is reduced in both diastole and systole: Time for a redefinition? Heart 2002;87:121-125.
13. Yu CM, Lin H, Yang H, Kong SL, Zhang Q, Lee SW. Progression of systolic abnormalities in patients with "isolated" diastolic heart failure and diastolic dysfunction. Circulation 2002;105:1195-1201.
14. Petrie MC, Caruana L, Berry C, McMurray JJ. Diastolic heart failure" or heart failure caused by subtle left ventricular systolic dysfunction? Heart 2002;87:29-31.
15. Borlaug BA, Melenovsky V, Russell SD, Kessler K, Pacak K, Becker LC, Kass DA. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 2006;114:2138-2147.
16. Maurer MS, King DL, El-Khoury Rumbarger L, Packer M, Burkhoff D. Left heart failure with a normal ejection fraction: Identification of different pathophysiologic mechanisms. J Card Fail 2005; 11:177-187.
17. Melenovsky V, Borlaug BA, Rosen B, et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: The role of atrial remodeling/dysfunction. J Am Coll Cardiol 2007;49:198-207.
18. Maurer MS, Burkhoff D, Fried LP, Gottdiener J, King DL, Kitzman DW. Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: The Cardiovascular Health Study. J Am Coll Cardiol 2007;49:972-981.
19. Ennezat PV, Lefetz Y, Marechaux S, et al. Left ventricular abnormal response during dynamic exercise in patients with heart failure and preserved left ventricular ejection fraction at rest. J Card Fail 2008;14:475-480.
20. Wang J, Khoury DS, Yue Y, Torre-Amione G, Nagueh SF. Preserved left ventricular twist and circumferential deformation, but depressed longitudinal and radial deformation in patients with diastolic heart failure. Eur Heart J 2008;29:1283-1289.
21. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: A community-based study. J Am Coll Cardiol 2009;53:1119-1126.
22. Borlaug BA, Lam CS, Roger VL, Rodeheffer RJ, Redfield MM. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 2009;54:410-418.
23. Tan YT, Wenzelburger F, Lee E, et al. The pathophysiology of heart failure with normal ejection fraction: Exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion. J Am Coll Cardiol 2009;54:36-46.
24. Phan TT, Abozguia K, Nallur Shivu G, et al. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol 2009;54:402-409.
25. Borlaug BA, Kass DA. Mechanisms of diastolic dysfunction in heart failure. Trends Cardiovasc Med 2006;16:273-279.
26. Klapholz M, Maurer M, Lowe AM, et al. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: Results of the New York Heart Failure Registry. J Am Coll Cardiol 2004;43:1432-1438.
27. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:e391-e479.
28. Burkhoff D, Maurer MS, Packer M. Heart failure with a normal ejection fraction: Is it really a disorder of diastolic function? Circulation 2003;107:656-658.
29. Bilchick KC, Duncan JG, Ravi R, et al. Heart failure-associated alterations in troponin I phosphorylation impair ventricular relaxation-after load and force-frequency responses and systolic function. Am J Physiol Heart Circ Physiol 2006;292:H318-H325.
30. Borlaug BA, Melenovsky V, Redfield MM, Kessler K, Chang HJ, Abraham TP, Kass DA. Impact of arterial load and loading sequence on left ventricular tissue velocities in humans. J Am Coll Cardiol 2007;50:1570-1577.
31. Leite-Moreira AF, Correia-Pinto J. Load as an acute determinant of end-diastolic pressure-volume relation. Am J Physiol Heart Circ Physiol 2001;280:H51-H59.
32. Leite-Moreira AF, Correia-Pinto J, Gillebert TC. Afterload induced changes in myocardial relaxation: A mechanism for diastolic dysfunction. Cardiovasc Res 1999;43:344-353.
33. Shapiro BP, Lam CS, Patel JB, et al. Acute and chronic ventricular-arterial coupling in systole and diastole. Insights from an elderly hypertensive model. Hypertension 2007;50:503-511.
34. Solomon SD, Janardhanan R, Verma A, et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: A randomised trial. Lancet 2007;369:2079-2087.
35. Fukuta H, Little WC. The cardiac cycle and the physiologic basis of left ventricular contraction, ejection, relaxation, and filling. Heart Fail Clin 2008;4:1-11.
36. Kass DA, Maughan WL, Guo ZM, Kono A, Sunagawa K, Sagawa K. Comparative influence of load versus inotropic states on indexes of ventricular contractility: Experimental and theoretical analysis based on pressure-volume relationships. Circulation 1987;76:1422-1436.
37. Aurigemma GP, Zile MR, Gaasch WH. Contractile behavior of the left ventricle in diastolic heart failure: With emphasis on regional systolic function. Circulation 2006;113:296-304.
38. Baicu CF, Zile MR, Aurigemma GP, Gaasch WH. Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation 2005;111:2306-2312.
39. Borlaug BA, Kass DA. Ventricular-vascular interaction in heart failure. Heart Fail Clin 2008;4:23-36.
40. Borlaug BA, Lam CSP, Olson TP, Flood KS, Johnson BD, Redfield MM. Cardiovascular reserve function in heart failure with preserved ejection fraction: Systolic versus diastolic determinants. Circulation (abs) 2008;118:S1022.
41. Brubaker PH, Joo KC, Stewart KP, Fray B, Moore B, Kitzman DW. Chronotropic incompetence and its contribution to exercise intolerance in older heart failure patients. J Cardiopulm Rehabil 2006;26:86-89.
42. Chattopadhyay S, Alamgir MF, Nikitin NP, Rigby AS, Clark AL, Cleland JG. Lack of diastolic reserve in patients with heart failure and normal ejection fraction. Circ Heart Fail 2009 Oct 22 [Epub ahead of print]. doi:.
43. Colucci WS, Ribeiro JP, Rocco MB, et al. Impaired chronotropic response to exercise in patients with congestive heart failure. Role of postsynaptic beta-adrenergic desensitization. Circulation 1989;80:314-323.
44. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol 2005;45:661-667.
45. Phan TT, Nallur Shivu G, Abozguia K, et al. Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction. Circ Heart Fail 2009 Nov 16 [Epub ahead of print]. doi:.
46. Smith CS, Bottomley PA, Schulman SP, Gerstenblith G, Weiss RG. Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation 2006;114:1151-1158.
47. Liu CP, Ting CT, Lawrence W, Maughan WL, Chang MS, Kass DA. Diminished contractile response to increased heart rate in intact human left ventricular hypertrophy. Systolic versus diastolic determinants. Circulation 1993;88:1893-1906.
48. Katz SD, Schwarz M, Yuen J, LeJemtel TH. Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure. Role of endothelium-derived vasodilating and vasoconstricting factors. Circulation 1993;88:55-61.
49. Hundley WG, Bayram E, Hamilton CA, et al. Leg flow-mediated arterial dilation in elderly patients with heart failure and normal left ventricular ejection fraction. Am J Physiol Heart Circ Physiol 2007;292:H1427-H1434.
50. Borlaug BA, Olson TP, Lam CS, Flood KS, Johnson BD, Redfield MM, Lerman A. Does endothelial dysfunction contribute to exercise limitation in heart failure with preserved ejection fraction?. J Am Coll Cardiol 2009; 53(10 Suppl A):A144-A197.
51. Chen CH, Nakayama M, Nevo E, Fetics BJ, Maughan WL, Kass DA. Coupled systolic-ventricular and vascular stiffening with age: Implications for pressure regulation and cardiac reserve in the elderly. J Am Coll Cardiol 1998;32:1221-1227.
52. Hundley WG, Kitzman DW, Morgan TM, et al. Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. J Am Coll Cardiol 2001;38:796-802.
53. He KL, Dickstein M, Sabbah HN, et al. Mechanisms of heart failure with well preserved ejection fraction in dogs following limited coronary microembolization. Cardiovasc Res 2004;64:72-83.
54. Gottdiener JS, Kitzman DW, Aurigemma GP, Arnold AM, Manolio TA. Left atrial volume, geometry, and function in systolic and diastolic heart failure of persons ≥ 65 years of age (the cardiovascular health study). Am J Cardiol 2006;97:83-89.
55. Fung JW, Sanderson JE, Yip GW, Zhang Q, Yu CM. Impact of atrial fibrillation in heart failure with normal ejection fraction: A clinical and echocardiographic study. J Card Fail 2007;13:649-655.
56. Kjaergaard J, Akkan D, Iversen KK, Kjoller E, Kober L, Torp-Pedersen C, Hassager C. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol 2007;99:1146-1150.
57. Wang J, Kurrelmeyer KM, Torre-Amione G, Nagueh SF. Systolic and diastolic dyssynchrony in patients with diastolic heart failure and the effect of medical therapy. J Am Coll Cardiol 2007;49:88-96.
58. Yu CM, Zhang Q, Yip GW, Lee PW, Kum LC, Lam YY, Fung JW. Diastolic and systolic asynchrony in patients with diastolic heart failure: A common but ignored condition. J Am Coll Cardiol 2007;49:97-105.
59. Shapiro BP, McGoon MD, Redfield MM. Unexplained pulmonary hypertension in elderly patients. Chest 2007;131:94-100.
60. Boilson BA, Schiger JA, Borlaug BA. Caveat Medicus! Pulmonary hypertension in the elderly: A word of caution. Eur J Heart Fail 2010;12:89-93.
61. Zile MR, Barst RJ, Bourge R, Redfield MM, Little WC. A phase 2 randomized, double-blind, placebo-controlled exploratory efficacy study of Sitaxsentan sodium to improve impaired exercise tolerance in subjects with diastolic heart failure. J Card Fail (abs) 2009;15(6 Suppl 1):S63.
62. Redfield MM, Lee KL, Braunwald E. Evaluating the effectiveness of sildenafil at improving health outcomes and exercise ability in people with diastolic heart failure (The RELAX Study). Available from: 2008; NCT00763867 [Accessed 20 November 2009].
63. Kass DA. An epidemic of dyssynchrony: But what does it mean? J Am Coll Cardiol 2008;51:12-17.
64. Witte KK, Clark AL. Why does chronic heart failure cause breathlessness and fatigue? Prog Cardiovasc Dis 2007;49:366-384.
65. Clark AL, Poole-Wilson PA, Coats AJ. Exercise limitation in chronic heart failure: Central role of the periphery. J Am Coll Cardiol 1996;28:1092-1102.
66. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007;50:2136-2144.
67. Ahmed A, Rich MW, Sanders PW, et al. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: A propensity matched study. Am J Cardiol 2007;99:393-398.
68. Abramov D, Cohen RS, Katz SD, Mancini D, Maurer MS. Comparison of blood volume characteristics in anemic patients with low versus preserved left ventricular ejection fractions. Am J Cardiol 2008;102:1069-1072.
69. Felker GM, Shaw LK, Stough WG, O'Connor CM. Anemia in patients with heart failure and preserved systolic function. Am Heart J 2006;151:457-462.
70. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008;52:818-827.
71. Latado AL, Passos LC, Darze ES, Lopes AA. Comparison of the effect of anemia on in-hospital mortality in patients with versus without preserved left ventricular ejection fraction. Am J Cardiol 2006;98:1631-1634.
72. Davie AP, Francis CM, Caruana L, Sutherland GR, McMurray JJ. Assessing diagnosis in heart failure: Which features are any use? QJM 1997;90:335-339.
73. Caruana L, Petrie MC, Davie AP, McMurray JJ. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from "diastolic heart failure" or from misdiagnosis? A prospective descriptive study. BMJ 2000;321:215-218.
74. Banerjee P, Banerjee T, Khand A, Clark AL, Cleland JG. Diastolic heart failure: Neglected or misdiagnosed? J Am Coll Cardiol 2002;39:138-141.
75. Cleland JG, Taylor J, Tendera M. Prognosis in heart failure with a normal ejection fraction. N Engl J Med 2007;357:829-830.
76. Ingle L, Cleland JG, Clark AL. Perception of symptoms is out of proportion to cardiac pathology in patients with "diastolic heart failure. Heart 2008;94:748-753.
77. Rutten FH, Cramer MJ, Grobbee DE, Sachs AP, Kirkels JH, Lammers JW, Hoes AW. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005;26:1887-1894.
78. Tschope C, Kasner M, Westermann D, Gaub R, Poller WC, Schultheiss HP. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: Correlation with echocardiographic and invasive measurements. Eur Heart J 2005;26:2277-2284.
79. Iwanaga Y, Nishi I, Furuichi S, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: Comparison between systolic and diastolic heart failure. J Am Coll Cardiol 2006;47:742-748.
80. Borlaug BA, Sorajja P, Nishimura RA, Lam CS, Redfield MM. Do exercise hemodynamics enhance diagnosis of heart failure with preserved ejection fraction? Circulation (abs) 2009;120:S756.
81. Henkel DM, Redfield MM, Weston SA, Gerber Y, Roger VL. Death in heart failure: A community perspective. Circ Heart Fail 2008;1:91-97.
82. Shah SJ, Gheorghiade M. Heart failure with preserved ejection fraction: Treat now by treating comorbidities. JAMA 2008;300:431-433.
83. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003;115:41-46.
84. Little WC, Zile MR, Klein A, Appleton CP, Kitzman DW, Wesley-Farrington DJ. Effect of losartan and hydrochlorothiazide on exercise tolerance in exertional hypertension and left ventricular diastolic dysfunction. Am J Cardiol 2006;98:383-385.
85. Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 1993;71:602-604.
86. Little WC, Brucks S. Therapy for diastolic heart failure. Prog Cardiovasc Dis 2005;47:380-388.
87. Bergstrom A, Andersson B, Edner M, Nylander E, Persson H, Dahlstrom U. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 2004;6:453-461.
88. Dobre D, van Veldhuisen DJ, DeJongste MJ, et al. Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival. Eur J Heart Fail 2007;9:280-286.
89. Farasat SM, Bolger DT, Shetty V, Menachery EP, Gerstenblith G, Kasper EK, Najjar SS. Effect of ß-blocker therapy on re-hospitalization rates in women versus men with heart failure and preserved ejection fraction. Am J Cardiol 2010;in press.
90. Hernandez AF, Hammill BG, O'Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure: Findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009;53:184-192.
91. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction ≥ 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol 1997;80:207-209.
92. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-225.
93. Ghio S, Magrini G, Serio A, et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: Results of the SENIORS echocardiographic substudy. Eur Heart J 2006;27:562-568.
94. van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 2009;53:2150-2158.
95. Borlaug BA. Treatment of heart failure with preserved ejection fraction. Curr Treat Options Cardiovasc Med 2009;11:79-87.
96. Davis BR, Kostis JB, Simpson LM, et al. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation 2008;118:2259-2267.
97. Yip GW, Wang M, Wang T, et al. The Hong Kong diastolic heart failure study: A randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 2008;94:573-580.
98. Paulus WJ, Shah AM. NO and cardiac diastolic function. Cardiovasc Res 1999;43:595-606.
99. Borlaug BA, Kass DA. Invasive hemodynamic assessment in heart failure. Heart Fail Clin 2009;5:217-228.
100. McCallister BD, Yipintsoi T, Hallermann FJ, Wallace RB, Frye RL. Left ventricular performance during mild supine leg exercise in coronary artery disease. Circulation 1968;37:922-931.
101. Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther 2009;122:216-238.
102. Setaro JF, Zaret BL, Schulman DS, Black HR, Soufer R. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990;66:981-986.
103. Hung MJ, Cherng WJ, Kuo LT, Wang CH. Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure. Int J Clin Prac 2002;56:57-62.
104. Chen CH, Nakayama M, Talbot M, et al. Verapamil acutely reduces ventricular-vascular stiffening and improves aerobic exercise performance in elderly individuals. J Am Coll Cardiol 1999;33:1602-1609.
105. Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: In vitro studies. Cardiovasc Res 1994;28:1863-1867.
106. Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004;110:558-565.
107. Gheorghiade M, Adams KF Jr., Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation 2004;109:2959-2964.
108. Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: The ancillary digitalis investigation group trial. Circulation 2006;114:397-403.
109. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: A preliminary report. Circulation 2005;112:357-363.
110. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231-1239.
111. Kass DA, Midei M, Brinker J, Maughan WL. Influence of coronary occlusion during PTCA on end-systolic and end-diastolic pressure-volume relations in humans. Circulation 1990;81:447-460.
112. Choudhury L, Gheorghiade M, Bonow RO. Coronary artery disease in patients with heart failure and preserved systolic function. Am J Cardiol 2002;89:719-722.
113. Kramer K, Kirkman P, Kitzman D, Little WC. Flash pulmonary edema: Association with hypertension and reoccurrence despite coronary revascularization. Am Heart J 2000;140:451-455.
114. Coletta AP, Cleland JG, Cullington D, Clark AL. Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452. Eur J Heart Fail 2008;10:917-920.
115. Velazquez EJ, Lee KL, O'Connor CM, et al. The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovas Surg 2007;134:1540-1547.
116. Gray BH, Olin JW, Childs MB, Sullivan TM, Bacharach JM. Clinical benefit of renal artery angioplasty with stenting for the control of recurrent and refractory congestive heart failure. Vasc Med (London, England) 2002;7:275-279.
117. Wheatley K, Ives N, Gray R, et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009;361:1953-1962.
118. Pickering TG, Herman L, Devereux RB, et al. Recurrent pulmonary oedema in hypertension due to bilateral renal artery stenosis: Treatment by angioplasty or surgical revascularisation. Lancet 1988;2:551-552.
119. Kitzman DW, Little WC, Brubaker PH, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002;288:2144-2150.
120. O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009;301:1439-1450.
121. Hambrecht RP, Gielen S, Adams V. Leipzig Exercise Intervention in Chronic Heart Failure and Aging (LEICA). Available from:. 2005;NCT00176319 [Accessed 20 November 2009].
122. Kitzman D. Exercise Intolerance in Elderly Patients With Diastolic Heart Failure (SECRET). Available from:. 2009;NCT00959660 [Accessed 20 November 2009].
123. Arbab-Zadeh A, Dijk E, Prasad A, et al. Effect of aging and physical activity on left ventricular compliance. Circulation 2004;110:1799-1805.
124. Stickland MK, Welsh RC, Petersen SR, et al. Does fitness level modulate the cardiovascular hemodynamic response to exercise? J Appl Physiol 2006;100:1895-1901.
125. Brenner DA, Apstein CS, Saupe KW. Exercise training attenuates age-associated diastolic dysfunction in rats. Circulation 2001;104:221-226.
126. Prasad A, Popovic ZB, Arbab-Zadeh A, et al. The effects of aging and physical activity on Doppler measures of diastolic function. Am J Cardiol 2007;99:1629-1636.
127. George KP, Naylor LH, Whyte GP, Shave RE, Oxborough D, Green DJ. Diastolic function in healthy humans: Non-invasive assessment and the impact of acute and chronic exercise. Eur J Appl Physiol 2010;108:1-14.
128. Maurer M. Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF). Available from:. 2006;NCT00286182 [Accessed 20 November 2009].
129. Borlaug BA, Melenovsky V, Marhin T, Fitzgerald P, Kass DA. Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation 2005;112:2642-2649.
130. Vlachopoulos C, Hirata K, O'Rourke MF. Effect of sildenafil on arterial stiffness and wave reflection. Vasc Med (London, England) 2003;8:243-248.
131. Takimoto E, Champion HC, Li M, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005;11:214-222.
132. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000;36:845-851.
133. Lewis GD, Lachmann J, Camuso J, et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007;115:59-66.
134. Chen HH. Heart failure: A state of brain natriuretic peptide deficiency or resistance or both! J Am Coll Cardiol 2007;49:1089-1091.
135. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-1697.
136. Li R. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT). Available from:. 2004;NCT00094302 [Accessed 20 November 2009].
137. Lai A, Frishman WH. Rho-kinase inhibition in the therapy of cardiovascular disease. Cardiol Rev 2005;13:285-292.
138. Kass DA. Restoration of Chronotropic Competence in Heart Failure Patients With Normal Ejection Fraction (RESET). Available from:. 2008;NCT00670111 [Accessed 20 November 2009].
139. McCaffrey DJ, McDonald K. If Channel Blockade With Ivabradine in Patients With Diastolic Heart Failure. Available from:. 2008;NCT00757055 [Accessed 20 November 2009].
140. Olshansky B, Sabbah HN, Hauptman PJ, Colucci WS. Parasympathetic nervous system and heart failure: Pathophysiology and potential implications for therapy. Circulation 2008;118:863-871.
141. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. Part II. Causal mechanisms and treatment. Circulation 2002;105:1503-1508.
142. Vaitkevicius PV, Lane M, Spurgeon H, et al. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci U S A 2001;98:1171-1175.
143. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, Lakatta EG. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001;104:1464-1470.
144. Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005;11:191-195.
145. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002;106:130-135.
146. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: Influence on cardiac form and function. Physiol Rev 2007;87:1285-1342.
147. Granzier HL, Labeit S. The giant protein titin: A major player in myocardial mechanics, signaling, and disease. Circ Res 2004;94:284-295.
148. Borbely A, Van Der Velden J, Papp Z, Bronzwaer JG, Edes I, Stienen GJ, Paulus WJ. Cardiomyocyte stiffness in diastolic heart failure. Circulation 2005;111:774-781.
149. van Heerebeek L, Borbely A, Niessen HW, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006;113:1966-1973.
150. Frenneaux M. Perhexiline Therapy in Heart Failure With Preserved Ejection Fraction Syndrome. Available from:. 2009;NCT00839228 [Accessed 20 November 2009].
151. Ekelund UE, Harrison RW, Shokek O, et al. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res 1999;85:437-445.
152. Hare JM, Mangal B, Brown J, et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 2008;51:2301-2309.
153. Moens AL, Takimoto E, Tocchetti CG, et al. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: Efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation 2008;117:2626-2636.
154. Moens AL, Kass DA. Therapeutic potential of tetrahydrobiopterin for treating vascular and cardiac disease. J Cardiovas Pharmacol 2007;50:238-246.
155. Sossalla S, Wagner S, Rasenack EC, et al. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts-role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol 2008;45:32-43.